RNAi-based nanomedicines for targeted personalized therapy

Ala Daka, Dan Peer

Research output: Contribution to journalReview article

111 Scopus citations

Abstract

RNA interference (RNAi) has just made it through the pipeline to clinical trials. However, in order for RNAi to serve as an ideal personalized therapeutics and be clinically approved-safe, specific, and potent strategies must be devised for efficient delivery of RNAi payloads to specific cell types, which despite the immense potential, remains a challenge. Through evaluating the recent reported studies in this field, we introduce the progress in designing targeted nano-scaled strategies that are anticipated to overcome the delivery drawbacks and along with the exciting "omics" discipline to personalize RNAi-based therapeutics.

Original languageEnglish (US)
Pages (from-to)1508-1521
Number of pages14
JournalAdvanced Drug Delivery Reviews
Volume64
Issue number13
DOIs
StatePublished - Oct 1 2012

Keywords

  • ApoB
  • BD
  • Clinical trials
  • CME
  • CNT
  • DC-6-14
  • DOPE
  • DOTAP
  • DOTMA
  • DsRNA
  • EPR
  • I.V.
  • In vivo
  • MAb
  • MiRNA
  • MPS
  • MW
  • Nanoparticles
  • NP
  • Nt
  • P.I.
  • PC
  • PEG
  • PEI
  • Personalized medicine
  • PK
  • RES
  • RISC
  • RNA
  • Short interfering RNA (siRNA)
  • ShRNA
  • SNALP
  • Systemic delivery
  • T
  • TLR

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'RNAi-based nanomedicines for targeted personalized therapy'. Together they form a unique fingerprint.

Cite this